Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Violacein is a natural bis-indole pigment primarily produced by the bacterium *Chromobacterium violaceum*. It is being developed by Farmabrasilis as a multi-functional therapeutic agent with reported cytotoxic, antibacterial, and antiparasitic activities. In oncology, violacein has demonstrated the ability to induce apoptosis in various cancer cell lines through mechanisms involving the generation of reactive oxygen species (ROS), activation of the p38 MAPK pathway, and modulation of p53 and NF-κB signaling. Beyond its antineoplastic potential, it exhibits potent activity against Gram-positive bacteria, including methicillin-resistant *Staphylococcus aureus* (MRSA), and shows promise as an antimalarial agent. It is currently in preclinical development for the treatment of cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on violacein.